Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain. more
Time Frame | GRFS | Sector | S&P500 |
---|---|---|---|
1-Week Return | 0.79% | -0.94% | -2.6% |
1-Month Return | -10.7% | -5.08% | -1.08% |
3-Month Return | -12.73% | -10.62% | 3.45% |
6-Month Return | 6.82% | -6.18% | 8.57% |
1-Year Return | -25.65% | 1.98% | 24.3% |
3-Year Return | -31.37% | -0.93% | 25.58% |
5-Year Return | -67.07% | 33.84% | 84.07% |
10-Year Return | -54.73% | 102.52% | 185.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 5.10B | 5.34B | 4.93B | 6.06B | 6.59B | [{"date":"2019-12-31","value":77.35,"profit":true},{"date":"2020-12-31","value":81.01,"profit":true},{"date":"2021-12-31","value":74.84,"profit":true},{"date":"2022-12-31","value":91.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 2.76B | 3.08B | 2.97B | 3.83B | 4.27B | [{"date":"2019-12-31","value":64.59,"profit":true},{"date":"2020-12-31","value":72.26,"profit":true},{"date":"2021-12-31","value":69.58,"profit":true},{"date":"2022-12-31","value":89.77,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 2.34B | 2.26B | 1.96B | 2.23B | 2.32B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":96.32,"profit":true},{"date":"2021-12-31","value":83.83,"profit":true},{"date":"2022-12-31","value":95.31,"profit":true},{"date":"2023-12-31","value":99.21,"profit":true}] |
Gross Margin | 45.92% | 42.23% | 39.78% | 36.80% | 35.24% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":91.97,"profit":true},{"date":"2021-12-31","value":86.64,"profit":true},{"date":"2022-12-31","value":80.14,"profit":true},{"date":"2023-12-31","value":76.73,"profit":true}] |
Operating Expenses | 1.22B | 1.28B | 1.40B | 1.53B | 1.58B | [{"date":"2019-12-31","value":76.91,"profit":true},{"date":"2020-12-31","value":80.76,"profit":true},{"date":"2021-12-31","value":88.35,"profit":true},{"date":"2022-12-31","value":96.5,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 1.13B | 996.13M | 595.06M | 805.68M | 737.92M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":88.05,"profit":true},{"date":"2021-12-31","value":52.6,"profit":true},{"date":"2022-12-31","value":71.21,"profit":true},{"date":"2023-12-31","value":65.22,"profit":true}] |
Total Non-Operating Income/Expense | (543.03M) | (359.12M) | (511.05M) | (907.09M) | (1.09B) | [{"date":"2019-12-31","value":-54303000000,"profit":false},{"date":"2020-12-31","value":-35912100000,"profit":false},{"date":"2021-12-31","value":-51105400000,"profit":false},{"date":"2022-12-31","value":-90708800000,"profit":false},{"date":"2023-12-31","value":-108803400000,"profit":false}] |
Pre-Tax Income | 817.10M | 878.63M | 350.45M | 361.26M | 224.02M | [{"date":"2019-12-31","value":93,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":39.89,"profit":true},{"date":"2022-12-31","value":41.12,"profit":true},{"date":"2023-12-31","value":25.5,"profit":true}] |
Income Taxes | 168.46M | 169.64M | 85.13M | 90.11M | 43.35M | [{"date":"2019-12-31","value":99.3,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":50.18,"profit":true},{"date":"2022-12-31","value":53.12,"profit":true},{"date":"2023-12-31","value":25.55,"profit":true}] |
Income After Taxes | 648.64M | 708.99M | 265.33M | 271.15M | 180.67M | [{"date":"2019-12-31","value":91.49,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":37.42,"profit":true},{"date":"2022-12-31","value":38.24,"profit":true},{"date":"2023-12-31","value":25.48,"profit":true}] |
Income From Continuous Operations | 648.64M | 708.99M | 265.33M | 271.15M | 138.29M | [{"date":"2019-12-31","value":91.49,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":37.42,"profit":true},{"date":"2022-12-31","value":38.24,"profit":true},{"date":"2023-12-31","value":19.51,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 625.15M | 618.55M | 265.33M | 208.28M | 59.31M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":98.94,"profit":true},{"date":"2021-12-31","value":42.44,"profit":true},{"date":"2022-12-31","value":33.32,"profit":true},{"date":"2023-12-31","value":9.49,"profit":true}] |
EPS (Diluted) | 1.18 | 1.20 | 0.87 | 0.20 | 0.46 | [{"date":"2019-12-31","value":98.33,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":72.28,"profit":true},{"date":"2022-12-31","value":16.34,"profit":true},{"date":"2023-12-31","value":38.23,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
GRFS | |
---|---|
Cash Ratio | 0.34 |
Current Ratio | 2.26 |
Quick Ratio | 0.79 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
GRFS | |
---|---|
ROA (LTM) | 2.87% |
ROE (LTM) | 2.71% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
GRFS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.61 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.26 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
GRFS | |
---|---|
Trailing PE | 35.00 |
Forward PE | 8.35 |
P/S (TTM) | 0.85 |
P/B | 0.91 |
Price/FCF | 33 |
EV/R | 2.02 |
EV/Ebitda | 9.64 |
PEG | 0.23 |
Grifols SA ADR (GRFS) share price today is $7.68
Yes, Indians can buy shares of Grifols SA ADR (GRFS) on Vested. To buy Grifols SA ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GRFS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Grifols SA ADR (GRFS) via the Vested app. You can start investing in Grifols SA ADR (GRFS) with a minimum investment of $1.
You can invest in shares of Grifols SA ADR (GRFS) via Vested in three simple steps:
The 52-week high price of Grifols SA ADR (GRFS) is $12.15. The 52-week low price of Grifols SA ADR (GRFS) is $5.3.
The price-to-earnings (P/E) ratio of Grifols SA ADR (GRFS) is 35
The price-to-book (P/B) ratio of Grifols SA ADR (GRFS) is 0.91
The dividend yield of Grifols SA ADR (GRFS) is 0.00%
The market capitalization of Grifols SA ADR (GRFS) is $7.13B
The stock symbol (or ticker) of Grifols SA ADR is GRFS